Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  TiGenix NV    TIG   BE0003864817

TIGENIX NV (TIG)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/10/2018 07/11/2018 07/12/2018 07/13/2018 07/16/2018 Date
1.78(c) 1.776(c) 1.776(c) 1.776(c) 1.776(c) Last
78 494 39 187 31 623 59 888 300 462 Volume
+0.11% -0.22% 0.00% 0.00% 0.00% Change
More quotes
Financials (EUR)
Sales 2018 25,8 M
EBIT 2018 -
Net income 2018 -23,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 6,00 M
EBIT 2019 -
Net income 2019 -59,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 20,4x
Capi. / Sales2019 87,6x
Capitalization 526 M
More Financials
Company
TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products.The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells.It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction,... 
More about the company
Latest news on TIGENIX NV
07/12TIGENIX : Takeda and TiGenix Announce Results of Second Acceptance Period for th..
AQ
07/10TAKEDA PHARMACEUTICAL : and TiGenix Announce Results of Second Acceptance Period..
AQ
07/09TIGENIX : Transparency Information
AQ
07/07TAKEDA PHARMACEUTICAL : and TiGenix Announce Results of Second Acceptance Period..
AQ
07/07TIGENIX : Takeda and TiGenix Announce Results of Second Acceptance Period for th..
AQ
07/06TIGENIX : Takeda and TiGenix Announce Results of Second Acceptance Period for th..
PU
07/06TIGENIX : Takeda and TiGenix Announce Results of Second Acceptance Period for th..
GL
07/02TIGENIX : Transparency Information ( EN - NL )
PU
07/02TIGENIX : Transparency Information
GL
07/02TIGENIX : Transparency notification pursuant to Article 14 of the Law of May 2, ..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/06Takeda and TiGenix Announce Results of Second Acceptance Period for the Volun.. 
07/06Takeda and TiGenix Announce Results of Second Acceptance Period for the Volun.. 
07/02Zacks: TIGENIX/S $TIG Given Average Recommendation of “Hold” by Analysts  
07/02$TIG NV Proxy Report 07/06/2018: In general, TiGenix is in compliance with t.. 
06/28TiGenix: Transparency notification pursuant to Article 14 of the Law of May .. 
More tweets
Qtime:40
News from SeekingAlpha
04/12Tigenix Sa reports FY results 
01/31BONE THERAPEUTICS : In (Re)Search For Money 
01/12Takeda's Offer On Tigenix - Good Deal Or Not? 
2017TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come 
2017Tigenix Sa reports FY results 
Chart TIGENIX NV
Duration : Period :
TiGenix NV Technical Analysis Chart | TIG | BE0003864817 | 4-Traders
Technical analysis trends TIGENIX NV
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 1,54 €
Spread / Average Target -13%
EPS Revisions
Managers
NameTitle
Jean Stéphenne Chairman
Claudia D'Augusta Chief Financial Officer & Compliance Officer
Wilfried Dalemans Chief Technical Officer
Marie Paule Richard Chief Medical Officer
Willy W. Duron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
TIGENIX NV82.72%614
GILEAD SCIENCES8.01%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.61%9 250